Inhibition of active HIV-1 replication by NF-κB inhibitor DHMEQ

Microbes and Infection

Volumn 12, Issue 5, 2010, Pages 400-408

  Miyake, Ariko ^a   Ishida, Takaomi ^a   Yamagishi, Makoto ^a   Hara, Takuma ^a   Umezawa, Kazuo ^b   Watanabe, Toshiki ^a   Horie, Ryouichi ^a,c  

^a Graduate School of Frontier Sciences   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DHMEQ; HIV 1; NF B

Indexed keywords

DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHYTOHEMAGGLUTININ; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE; VESICULAR STOMATITIS VIRUS; VIRUS EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION; WESTERN BLOTTING;

ANTI-HIV AGENTS; BENZAMIDES; CELL LINE; CELLS, CULTURED; CYCLOHEXANONES; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; NF-KAPPA B; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 77950865072     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.02.004     Document Type: Article

References (36)

1. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 16 (2008) 138-145
2. Nabel G., and Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326 (1987) 711-713
3. Griffin G.E., Leung K., Folks T.M., Kunkel S., and Nabel G.J. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature 339 (1989) 70-73
4. Leonard J., Parrott C., Buckler-White A.J., Turner W., Ross E.K., Martin M.A., and Rabson A.B. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J. Virol. 63 (1989) 4919-4924
5. Parrott C., Seidner T., Duh E., Leonard J., Theodore T.S., Buckler-White A., Martin M.A., and Rabson A.B. Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes. J. Virol. 65 (1991) 1414-1419
6. Lapointe R., Lemieux R., and Darveau A. HIV-1 LTR activity in human CD40-activated B lymphocytes is dependent on NF-kappaB. Biochem. Biophys. Res. Commun. 229 (1996) 959-964
7. Mallardo M., Dragonetti E., Baldassarre F., Ambrosino C., Scala G., and Quinto I. An NF-kappaB site in the 5′-untranslated leader region of the human immunodeficiency virus type 1 enhances the viral expression in response to NF-kappaB-activating stimuli. J. Biol. Chem. 271 (1996) 20820-20827
8. Takada N., Sanda T., Okamoto H., Yang J.P., Asamitsu K., Sarol L., Kimura G., Uranishi H., Tetsuka T., and Okamoto T. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions. J. Virol. 76 (2002) 8019-8030
9. Asamitsu K., Yamaguchi T., Nakata K., Hibi Y., Victoriano A.F., Imai K., Onozaki K., Kitade Y., and Okamoto T. Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB kinase with noraristeromycin. J. Biochem. 144 (2008) 581-589
10. Victoriano A.F., Asamitsu K., Hibi Y., Imai K., Barzaga N.G., and Okamoto T. Inhibition of human immunodeficiency virus type 1 replication in latently infected cells by a novel IkappaB kinase inhibitor. Antimicrob. Agents Chemother. 50 (2006) 547-555
11. Sanchez-Duffhues G., Calzado M.A., de Vinuesa A.G., Caballero F.J., Ech-Chahad A., Appendino G., Krohn K., Fiebich B.L., and Munoz E. Denbinobin, a naturally occurring 1,4-phenanthrenequinone, inhibits HIV-1 replication through an NF-kappaB-dependent pathway. Biochem. Pharmacol. 76 (2008) 1240-1250
12. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25 (2006) 6680-6684
13. Matsumoto N., Ariga A., To-e S., Nakamura H., Agata N., Hirano S., Inoue J., and Umezawa K. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 10 (2000) 865-869
14. Yamamoto M., Horie R., Takeiri M., Kozawa I., and Umezawa K. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J. Med. Chem. 51 (2008) 5780-5788
15. Watanabe M., Nakashima M., Togano T., Higashihara M., Watanabe T., Umezawa K., and Horie R. Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ. Biochem. Biophys. Res. Commun. 376 (2008) 310-314
16. Ariga A., Namekawa J., Matsumoto N., Inoue J., and Umezawa K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 277 (2002) 24625-24630
17. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., and Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59 (1986) 284-291
18. Kuwata T., Igarashi T., Ido E., Jin M., Mizuno A., Chen J., and Hayami M. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication. J. Gen. Virol. 76 Pt 9 (1995) 2181-2191
19. Fukumori T., Akari H., Yoshida A., Fujita M., Koyama A.H., Kagawa S., and Adachi A. Regulation of cell cycle and apoptosis by human immunodeficiency virus type 1 Vpr. Microbes Infect. 2 (2000) 1011-1017
20. Willey R.L., Smith D.H., Lasky L.A., Theodore T.S., Earl P.L., Moss B., Capon D.J., and Martin M.A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62 (1988) 139-147
21. Andrews N.C., and Faller D.V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucl. Acids Res. 19 (1991) 2499
22. Inoue J., Kerr L.D., Ransone L.J., Bengal E., Hunter T., and Verma I.M. c-rel activates but v-rel suppresses transcription from kappa B sites. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 3715-3719
23. Takebe Y., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., Yoshida M., and Arai N. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8 (1988) 466-472
24. Ishida T., Hamano A., Koiwa T., and Watanabe T. 5′ long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology 3 (2006) 69
25. Brussel A., and Sonigo P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J. Virol. 77 (2003) 10119-10124
26. Demarchi F., d'Adda di Fagagna F., Falaschi A., and Giacca M. Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1. J. Virol. 70 (1996) 4427-4437
27. Demarchi F., Gutierrez M.I., and Giacca M. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J. Virol. 73 (1999) 7080-7086
28. Kwon H.S., Brent M.M., Getachew R., Jayakumar P., Chen L.F., Schnolzer M., McBurney M.W., Marmorstein R., Greene W.C., and Ott M. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3 (2008) 158-167
29. Stevenson M., Stanwick T.L., Dempsey M.P., and Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. Embo J. 9 (1990) 1551-1560
30. Pereira L.A., Bentley K., Peeters A., Churchill M.J., and Deacon N.J. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucl. Acids Res. 28 (2000) 663-668
31. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., and Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 (1990) 213-222
32. Bristow C.L., Wolkowicz R., Trucy M., Franklin A., Di Meo F., Kozlowski M.T., Winston R., and Arnold R.R. NF-kappaB signaling, elastase localization, and phagocytosis differ in HIV-1 permissive and nonpermissive U937 clones. J. Immunol. 180 (2008) 492-499
33. Bossis G., Salinas S., Cartier C., Devaux C., and Briant L. NF-kappaB activation upon interaction of HIV-1 envelope glycoproteins with cell surface CD4 involves IkappaB kinases. FEBS Lett. 516 (2002) 257-264
34. Helbig G., Christopherson II K.W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D., Broxmeyer H.E., and Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278 (2003) 21631-21638
35. Liu R., Zhao X., Gurney T.A., and Landau N.R. Functional analysis of the proximal CCR5 promoter. AIDS Res. Hum. Retroviruses 14 (1998) 1509-1519
36. Umezawa K. Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci. 97 (2006) 990-995